- Report
- September 2024
- 110 Pages
Global
From €5689EUR$5,950USD£4,762GBP
- Report
- March 2025
- 200 Pages
Global
From €4293EUR$4,490USD£3,593GBP
- Report
- February 2025
- 200 Pages
Global
From €4293EUR$4,490USD£3,593GBP
- Report
- October 2024
- 175 Pages
Global
From €4780EUR$5,000USD£4,002GBP
- Report
- September 2024
- 175 Pages
Global
From €4780EUR$5,000USD£4,002GBP
- Report
- May 2024
- 128 Pages
Global
From €6214EUR$6,499USD£5,201GBP
- Report
- May 2024
- 140 Pages
Global
From €6214EUR$6,499USD£5,201GBP
- Report
- August 2024
- 150 Pages
Global
From €2667EUR$2,789USD£2,232GBP
- Report
- February 2025
- 184 Pages
Global
From €4302EUR$4,500USD£3,601GBP
- Report
- June 2024
- 183 Pages
Global
From €4302EUR$4,500USD£3,601GBP
- Report
- May 2024
- 213 Pages
Global
From €4776EUR$4,995USD£3,998GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3098EUR$3,240USD£2,593GBP
€3442EUR$3,600USD£2,881GBP
- Report
- October 2022
- 138 Pages
Global
From €4255EUR$4,450USD£3,561GBP
- Report
- February 2023
- 107 Pages
Global
From €7171EUR$7,500USD£6,002GBP
- Report
- February 2024
- 30 Pages
Global
From €3107EUR$3,250USD£2,601GBP
- Report
- January 2024
- 189 Pages
Global
From €7171EUR$7,500USD£6,002GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1434EUR$1,500USD£1,200GBP
- Report
- February 2024
- 70 Pages
United States
From €4541EUR$4,750USD£3,802GBP
- Report
- April 2024
- 30 Pages
Global
From €3107EUR$3,250USD£2,601GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1434EUR$1,500USD£1,200GBP

Empagliflozin is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to lower blood sugar levels. Empagliflozin is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Empagliflozin is marketed by several pharmaceutical companies, including Boehringer Ingelheim, Eli Lilly, and Merck. It is available in tablet form and is taken once daily. It is also available in combination with other diabetes medications, such as metformin and linagliptin. Show Less Read more